Latest news with #Lactococcuslactis
Economic Times
20-07-2025
- Health
- Economic Times
Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway
The Indian Council of Medical Research (ICMR), through its Regional Medical Research Centre, Bhubaneswar (RMRCBB) and National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology-National Institute of Immunology (DBT-NII), is currently developing a novel recombinant chimeric malaria vaccine candidate, named AdFalciVax. ADVERTISEMENT AdFalciVax is the first indigenous recombinant chimeric malaria vaccine specifically designed to target two critical stages of Plasmodium falciparum, the parasite responsible for the most lethal form of malaria. The vaccine aims to protect against human infection while also reducing vector-borne community transmission of the parasite. According to the release, the vaccine has demonstrated excellent efficacy in the preclinical stage of development. Preclinical data suggest that AdFalciVax may have advantages over existing single-stage vaccines, including broader protection by targeting two vulnerable parasite stages, lower risk of immune evasion, potential for better long-term immunity, and extended thermal stability with functionality maintained for over nine months at room is a recombinant multistage vaccine produced in Lactococcus lactis, designed to protect both individual humans and reduce the community transmission represents one of the most advanced malaria vaccine candidates globally, with a rational design targeting two key stages of the parasite. This vaccine consists of a stable and functional recombinant chimaera between antigenic components that promises dual protection. ADVERTISEMENT ICMR intends to license the technology for AdFalciVax to eligible organisations and manufacturers for further development, manufacture, and commercialisation under non-exclusive agreements. This approach aims to enable wider outreach and maximise public health benefits. All collaborations will adhere to ICMR's Intellectual Property Policy. ADVERTISEMENT As an indigenously developed vaccine candidate that fulfils the Make in India mandate, AdFalciVax holds the potential to contribute substantially to malaria eradication by preventing infection and minimising community information is provided for awareness purposes only. The vaccine candidate is in its early research and development phases and is not yet available for any clinical use or commercialisation. ADVERTISEMENT (You can now subscribe to our Economic Times WhatsApp channel)
Yahoo
10-06-2025
- Health
- Yahoo
Akesis Biologics Launches MastGut: A Breakthrough Supplement That Uses DUSP10 Enzyme to Support Gut and Colorectal Health
SINGAPORE, June 10, 2025 /PRNewswire/ -- Akesis Biologics, a biotechnology spin-off from the National University of Singapore (NUS), has officially launched its flagship gut health product, MastGut — a pioneering supplement that delivers therapeutic protection directly to the gut. Built on years of academic research and published findings in Nature Oncogene, MastGut brings an innovative approach to the consumer health space: using probiotic delivery of the DUSP10[1] enzyme to reduce gut inflammation and support long-term colorectal health. Colorectal cancer is the second leading cause of cancer-related deaths globally, and gut inflammation is on the rise in modern lifestyles. MastGut is developed with a novel, science-inspired approach grounded in academic research, aiming to support overall gut wellness through carefully selected ingredients.. "Most people think of probiotics as general digestive aids," says Prof. Zhang Yongliang, Co-founder and CEO of Akesis. "MastGut takes it much further. We intend to deliver an active functional protein that regulates inflammation and suppresses tumor-promoting enzyme activities — all using a probiotic vehicle." What is DUSP10[1]? A Scientific Breakthrough in Gut Health Unlike traditional supplements that rely on herbs or general bacterial strains, MastGut uses Lactococcus lactis, a food-grade probiotic commonly found in fermented dairy, as a delivery vehicle, to transport an enzyme known to reduce inflammation and suppress overactive cellular signalling underlying the development of colorectal cancer. This innovative method allows DUSP10 to be directly absorbed by intestinal cells, where it gets to work — without colonizing the gut. A Scientific Approach to Everyday Wellness DUSP10's function is well documented in cancer biology. Studies show that it acts as a brake on the MAPK pathway, a chain of molecular signals often overactivated in gut inflammation and cancer. In knockout mouse models, loss of DUSP10 led to increased tumor formation and gut damage. In contrast, higher expression of DUSP10 in human patients has been linked to better colorectal cancer outcomes. MastGut harnesses this science in a consumer-friendly format: a daily capsule that delivers the benefits of DUSP10 safely and effectively. "This isn't just another supplement. MastGut sits at the intersection of therapeutic treatment and nutritional science," says Dr. Chin Wen Png, Co-founder and CTO of Akesis. "It's for people who care about long-term gut health, cancer risk management, and the science behind what they put in their body." A New Frontier in Gut & Cancer Prevention MastGut represents a breakthrough in the way we think about preventive healthcare. By harnessing protein science to address inflammation and tumor suppression, it has the potential to benefit millions living with digestive discomfort, chronic inflammation, or increased colorectal cancer risk. "We are proud to see the launch of MastGut by Akesis Biologics, an NUS spin-off nurtured through our Graduate Research Innovation Programme (GRIP). This achievement underscores how NUS Enterprise's support and mentorship can transform cutting-edge research into impactful, real-world solutions. Akesis Biologics' successful journey from lab to market exemplifies our ongoing commitment to nurturing deep tech ventures and empowering them to create meaningful societal impact," said Associate Professor Benjamin Tee, Vice President (Ecosystem Building), NUS Enterprise. Akesis Biologics is currently engaging with hospitals, pharmacies, and research partners to broaden MastGut's access and impact across Asia and beyond. About Akesis Biologics Founded by leading scientists from NUS, Akesis Biologics is a Singapore-based biotech company focused on development of products to improve gut health. With expertise in inflammation, cancer biology, and clinical translation, Akesis aims to bridge the gap between academic innovation and practical health solutions. MastGut is the company's first commercial product, backed by years of R&D, IP protection, and real-world applicability. Reference: [1]Png, C.W., Weerasooriya, M., Guo, J., James, S.J., Poh, H.M., Osato, M., Flavell, R.A., Dong, C., Yang, H., and Zhang, Y. 2016. DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis. Oncogene 35:206-17. PMID: 25772234 View original content: SOURCE Akesis Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
